Ping An Biomedical Co., Ltd. is a US-listed company in the textiles industry. Its financial year ends in September.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: cash-flow, stock-pay or share-count figures missing or out of date.
Price vs value
Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.
Ping An Biomedical Co., Ltd. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds4 adding, 0 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Ping An Biomedical Co., Ltd.'s trailing-twelve-month revenue fell 61.1% year on year, with a free-cash-flow margin of -18.8%. Where it lags: revenue growth of -61.1% ranks 449 of 452 consumer discretionary companies we cover.
Current signal Revenue growth decelerating: TTM revenue growth slowed to -61.1% (-64.9pp vs the prior quarter).
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Ping An Biomedical Co., Ltd.'s latest figures clears our strength thresholds.
Things to watch
- Revenue shrinking. Revenue fell 61.1% over the last 12 months.
- Growth slowing. The growth rate is 64.9 points lower than a quarter earlier.
- Loss-making. Operating margin is -43.1%: costs exceed revenue.
- Margins narrowing. Operating margin is down 43.0 points on a year ago.
- Burning cash. Free cash flow was -18.8% of revenue over the last 12 months.
- Share dilution. Diluted shares rose 2.7% in a year.
Price chart
- 1 day-8.6%
- 1 week+4.5%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $4.7M
- Operating margin
- -43.1%
- Net margin
- -37.6%
- EPS (TTM, diluted)
- $-0.10
Growth
- Revenue growth
- −61.1%
- Change in growth rate
- −64.9 pts
- Share count change
- +2.7%
Cash
- Free cash flow (TTM)
- -$892,059
- FCF margin
- -18.8%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for PASW from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Ping An Biomedical Co., Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 8.8%: the 10-year Treasury yield (4.9%) plus a beta of 0.85 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | ~$0.0 ~$0.0–$0.1 | Left out: out of range vs price (0.01x) |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Ping An Biomedical Co., Ltd. with Consumer Discretionary sector in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Ping An Biomedical Co., Ltd.: too few analysts cover it.
Positioning
- Short interest
- 0.3% of tradable shares
- Days to cover
- 0.4 at average volume
- Short interest, 1 month
- −20% to October 15, 2026
- Held by institutions
- 0% of shares
- Held by insiders
- 12.1% of shares
- Employees
- 7 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Ping An Biomedical Co., Ltd. in five measures
Fundamentals
Financial statements
| Fiscal year | 2023 Sept 2023 | 2024 Sept 2024 | 2025 Sept 2025 |
|---|---|---|---|
| Income | |||
| Revenue | 12 | 12 | 5 |
| Gross profit | 1 | 1 | 0 |
| EBITDA | 0 | 0 | −2 |
| Operating income | 0 | −0 | −2 |
| Net income | −0 | −0 | −2 |
| Diluted EPS | −$0.01 | −$0.01 | −$0.10 |
| Growth (year on year) | |||
| Revenue | — | +3.8% | −61.1% |
| Margins | |||
| Gross margin | 5.1% | 6.2% | 2.8% |
| EBITDA margin | 0.8% | 0.0% | −43.0% |
| Operating margin | 0.7% | −0.0% | −43.1% |
| Net margin | −1.2% | −1.5% | −37.6% |
| Cash flow | |||
| Cash from operations | −1 | 2 | −1 |
| Balance sheet | |||
| Cash | 0 | 0 | 0 |
| Total debt | 0 | 1 | 1 |
| Net debt (negative = net cash) | −0 | 1 | 1 |
| Diluted shares | 18m | 18m | 18m |
| Returned to shareholders | |||
| Dividends | 1 | 0 | — |
| Total returned | 1 | 0 | — |
Financial health
- Short-term assets cover short-term liabilities $9m of assets due within a year against $3m of liabilities due within a year.
- Short-term assets cover long-term liabilities $9m short-term assets against $13,443 of longer-dated liabilities.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$2m against $42,577 of interest.
Dividends, buybacks and capital spending
- Dividends (TTM)
- $44,756
- Returned to shareholders
- 2%
- of free cash flow
- Diluted share count
- +2.7%
- year over year
- Days sales outstanding
- 183 days
- receivables vs revenue
Competitors: side by side with peers
| Last 12 months unless stated | PASW | NTRP | XELB | UZX | LXEH | MSN | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $5m | $5m | $5m | $5m | $4m | $6m | $1.4bn |
| Revenue growth, last 12 months | −61.1% | 356.8% | −21.2% | −50.5% | −5.9% | −44.6% | 4.2% |
| Revenue growth, 3-year average | — | — | −40.3% | — | — | −10.4% | 2.4% |
| Revenue growth, latest quarter | — | −27.8% | −15.1% | — | — | −37.1% | 3.6% |
| Gross margin | 2.8% | 17.3% | 94.6% | 72.6% | −38.7% | 10.6% | 37.5% |
| Operating margin | −43.1% | −306.2% | −282.6% | −90.4% | −118.0% | −74.7% | 4.2% |
| Operating margin, 3-year average | — | −784.6% | −262.0% | — | — | −56.7% | 4.5% |
| Net margin | −37.6% | −319.8% | −343.7% | −144.5% | −395.4% | −65.5% | 2.4% |
| Cash from operations / revenue | −18.8% | −184.6% | −130.9% | −91.9% | <−999% | −71.4% | 7.8% |
| Free-cash-flow margin | −18.8% | −212.6% | −130.9% | −95.2% | <−999% | −59.0% | 4.1% |
| Free-cash-flow margin, 3-year average | — | −538.5% | −100.1% | — | — | −51.3% | 4.1% |
| Stock pay / revenue | — | 0.9% | 14.2% | 23.7% | — | 0.0% | 0.8% |
| Change in share count | 2.7% | — | 0.0% | 173.6% | >999% | 0.0% | 0.0% |
Peer comparison
| Measure | Company | Peer median | Rank |
|---|---|---|---|
| Revenue growth Growth | -61.1% | 4.3% | 449 of 452 |
| Change in growth rate Growth | -64.9pp | -0.0pp | 445 of 452 |
| Gross margin Profitability | 2.8% | 37.1% | 344 of 355 |
| Operating margin Profitability | -43.1% | 4.1% | 374 of 415 |
| Net margin Profitability | -37.6% | 2.5% | 413 of 454 |
| Free-cash-flow margin Cash generation | -18.8% | 4.1% | 405 of 449 |
| Change in share count Balance sheet | 2.7% | 0.0% | 305 of 408 |
| Days sales outstanding Balance sheet | 183 days | 23 days | 290 of 299 |
Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).
Who owns it
Funds buying and selling- Reported value
- $49,427
- Institutions reporting
- 4
- Positions opened / closed
- 4 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Xtx Topco Ltd | $22,337 | 135K | 45.2% | — |
| Citadel Advisors LLC | $18,953 | 114K | 38.3% | — |
| Virtu Financial LLC | $6,000 | 37K | 12.1% | — |
| Two Sigma Securities, LLC | $2,137 | 13K | 4.3% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Ping An Biomedical Co., Ltd.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Ping An Biomedical Co., Ltd. in brief
- What does Ping An Biomedical Co., Ltd. do?
- Ping An Biomedical Co., Ltd. is a US-listed company in the textiles industry. Its financial year ends in September.
- What is Ping An Biomedical Co., Ltd.'s stock ticker?
- Ping An Biomedical Co., Ltd. trades under the ticker PASW on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is Ping An Biomedical Co., Ltd.'s revenue, and how fast is it growing?
- Over its most recent trailing twelve months, Ping An Biomedical Co., Ltd. reported revenue of $4.7M, 61.1% lower than a year earlier, according to its SEC filings.
- What is Ping An Biomedical Co., Ltd.'s free cash flow?
- Ping An Biomedical Co., Ltd.'s free-cash-flow margin is -18.8% of revenue over the trailing twelve months, ranking 405 of the 449 consumer discretionary companies we cover.
- Who are Ping An Biomedical Co., Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Xtx Topco Ltd, Citadel Advisors LLC and Virtu Financial LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Does Ping An Biomedical Co., Ltd. pay a dividend?
- Yes: Ping An Biomedical Co., Ltd. paid $44,756 in dividends over the trailing twelve months.
- Who are Ping An Biomedical Co., Ltd.'s competitors?
- In our Textiles peer group, the companies closest to Ping An Biomedical Co., Ltd. are Nexttrip, Inc., Xcel Brands, Inc., Linkage Global Inc, Lixiang Education Holding Co. Ltd. and Emerson Radio Corp. The side-by-side comparison below sets their revenue, margins and growth against Ping An Biomedical Co., Ltd.'s.
Follow research on Ping An Biomedical Co., Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.